Marketing Authorizations, Financial Results, Public Offering and Leadership Transitions - Research Report on Regeneron, Dendreon, Dyax, Techne, and ICU Medical Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, November 15, 2013 NEW YORK, November 15, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Dendreon Corp. (NASDAQ: DNDN), Dyax Corp. (NASDAQ: DYAX), Techne Corp. (NASDAQ: TECH), and ICU Medical, Inc. (NASDAQ: ICUI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Regeneron Pharmaceuticals, Inc. Research Report On November 7, 2013, Regeneron Pharmaceuticals, Inc. (Regeneron) along with Bayer HealthCare (Bayer) announced the submission of an application by Bayer for the marketing authorization of EYLEA® (aflibercept) Injection for the treatment of patients with Diabetic Macular Edema in the European Union. Regeneron stated that it has also submitted a supplemental Biologic Licensing Application (BLA) for EYLEA in this indication to the U.S. Food and Drug Administration (FDA). George D. Yancopoulos, M.D., Ph. D., Chief Scientific Officer of Regeneron and President of Regeneron Laboratories said, "Diabetes is a growing, worldwide health concern and DME is a major cause of vision loss in those with diabetic retinopathy. We are pleased with this regulatory submission in a third indication for EYLEA in Europe and, if approved, hope to be able to offer physicians and patients a new treatment option." According to the release, Bayer HealthCare and Regeneron are collaborating on the global development of EYLEA, wherein Regeneron maintains exclusive rights to EYLEA in the United States and Bayer licensed the exclusive marketing rights outside the United States. The Full Research Report on Regeneron Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/8ea7_REGN -- Dendreon Corp. Research Report On November 12, 2013, Dendreon Corp. (Dendreon) reported its Q3 2013 financial results with net product revenue of $68 million compared to $77.9 million in Q3 2012. Net loss for the quarter totaled $67.2 million or $0.44 per diluted share compared to a net loss of $154.9 million or $1.04 per diluted share in Q3 2012. As of September 30, 2013, the Company had a total of $233.3 million in cash, cash equivalents, and short-term and long-term investments. John H. Johnson, Chairman, President and CEO of Dendreon said, "We have seen a strengthening of our business during the past two months. In fact, in October, we saw more patient enrollments than any other month this year. Should these enrollments convert to infusions at our historical rate, we expect that this will bring benefit to both the fourth quarter of this year and the first quarter of next year." The Full Research Report on Dendreon Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/de0c_DNDN -- Dyax Corp. Research Report On October 18, 2013, Dyax Corp. (Dyax) announced that the underwriters of its earlier announced public offering have exercised their option to purchase an additional 1,384,615 shares of the Company's common stock at a price to the public of $6.50 per share. Dyax stated that after including net proceeds from the exercise of option, the aggregate net proceeds from the offering totals approximately $64.7 million, after deducting the underwriting discount and other estimated offering expenses. The Company added that it plans to use the net proceeds from this offering to fund research and development activities, including the development of DX-2930, a therapeutic candidate for the prophylactic treatment of hereditary angioedema (HAE), and for general corporate purposes. The Full Research Report on Dyax Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/58ae_DYAX -- Techne Corp. Research Report On October 29, 2013, Techne Corp. (Techne) reported its Q1 FY 2014 financial results (period ended September 30, 2013) with net sales of $85.7 million, up 14.2% YoY. Net earnings arrived at $27.4 million or $0.74 per diluted share compared to $25.7million or $0.70 per diluted share in Q1 FY 2013. Adjusted earnings totaled $30.7 million, up 11.6% YoY, while cash generated from operations for the quarter increased by 11.4% YoY to $32.6 million. Capital expenditures for the quarter were $3.8 million. The Full Research Report on Techne Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/b071_TECH -- ICU Medical, Inc. Research Report On October 21, 2013, ICU Medical Inc. (ICU Medical) announced that Dr. George Lopez will step down as the Company's President and CEO due to health reasons. The Company stated that he will continue in his role as Chairman of the Board and will remain an employee in the Research and Development Department. ICU Medical also announced that its Board of Directors has appointed Steven Riggs, current Vice President of Operations, as acting CEO, with immediate effect. According to the Company, Mr. Riggs has served as Vice President of Operations since 2002, wherein he was responsible for all of the Company's worldwide operations, including management of its supply chain. Dr. Michael Kovalchik, Lead Director of ICU Medical said, "The Board has complete confidence that Steven Riggs is the right person during this period. Steven's many years of service to ICU Medical have demonstrated remarkable talent in improving our efficiencies, driving our Company as a low cost leader, and positioning us for profitable expansion." The Full Research Report on ICU Medical, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/be3b_ICUI ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 1.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 2.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 3.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. SOURCE Analysts' Corner Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Marketing Authorizations, Financial Results, Public Offering and Leadership Transitions - Research Report on Regeneron,
Press spacebar to pause and continue. Press esc to stop.